MFN News Items – Page 9

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment of warrants of series TO13B has been set to December 23, 2022. The exercise period to subscribe for new shares with the support of warrants of series TO13B will be from and including February 23, 2023, to and including March 8, 2023. The first day of trading in the warrants of series TO13B on Nasdaq First North Growth Market will be on December 28, 2022.

As announced by press release on November 28, 2022, iZafe has completed a directed issue of shares and warrants of series TO13B (the “Directed Issue”). In order to give existing shareholders in the Company the opportunity to compensate for the dilution the Directed Issue entails, the Board of Directors of iZafe has also decided to issue warrants of series TO13B (same series as in the Directed Issue) to the Company, which then are allotted free of charge to the shareholders in the Company.

The record date to receive warrants of series TO13B has been set to December 23, 2022. Therefore, the last day of trading in the Company’s share including the right to receive warrants is December 21, 2022, and the first day of trading in the Company’s share excluding the right to receive warrants is December 22, 2022.

The Company’s existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date.

Terms and information regarding warrants of series TO13B

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent of the numbers of shares and approximately 42.69 percent of the votes.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the warrants of series TO13B.

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe Group AB (publ) hereby announces that the company has entered into an agreement with Mangold regarding the service as Certified Adviser.

Mangold will take over as Certified Adviser (CA) on 1 April 2023. Until then, FNCA will continue to act as Certified Adviser for the company.

About Us

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders

iZafe Group AB (publ) ("iZafe" or the "Company") has today entered into a share purchase agreement with the owners of Pilloxa AB ("Pilloxa") regarding the acquisition of all outstanding shares of Pilloxa in accordance with the letter of intent communicated by press release on August 18, 2022. Access to the shares in Pilloxa was completed today. iZafe has also successfully completed a directed issue of 20,833,334 units, each unit consisting of one (1) share and two (2) warrants of series TO13B. The subscription price per unit amounts to SEK 0.24, corresponding to a price per share of SEK 0.24 as the warrants are issued free of charge and the Company is thereby provided with approximately SEK 5 million before transaction costs (the "Directed Issue"). Qualified investors such as Jan Hardenborg, Eva Redhe, Fredrik Sjödin, Filippa Lindström, Karin Forseke, Peter Jörgensen, Lars Wedenborn and Mangold Fondkommission have through subscription commitments undertaken to participate in the Directed Issue. The Company has also decided to distribute 76,890,165 warrants of series TO13B to all shareholders in the Company after the acquisition of Pilloxa to capitalize the Company and to compensate for the dilution from the Directed Issue.

The Directed Issue

The Board of Directors of iZafe has, with the support of the authorization received at the Extraordinary General Meeting on September 28, 2022, today decided to carry out a directed issue of 20,833,334 units with deviation from existing owners' preferential rights, each unit consists of one (1) share and two (2) warrants of series TO13B. The subscription price per unit amounts to SEK 0.24, corresponding to a price per share of SEK 0.24, the warrants are issued free of charge. The Company receives approximately SEK 5 million before deductions for transaction costs. The subscription price for the Directed Issue has been determined through arm's length negotiations with several strategic and long-term investors over a period of time. The subscription price corresponds to a discount of 10 percent in relation to the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the last five (5) trading days, from and including November 22, 2022, to and including November 28, 2022, which amounted to approximately 0.262 SEK. The Board of Directors thus assesses the subscription price to be at market terms.

Background and motive for the Directed Issue

In order to satisfy the demand from existing customers, as well as meet the demand from new customers, iZafe deems it necessary to raise additional capital. iZafe intends to use the issue proceeds from the Directed Issue to increase sales of Dosell and Pilloxa's solutions.

More specifically, the Company intends to use the issue proceeds for:

Sales efforts of Dosell against Pilloxa's established customers and network.
Sales efforts of Pilloxa’s solutions towards iZafe’s partner network.
Integration between Dosell and Pilloxa's system and product.

The reason for that, and for the deviation from the shareholders' preferential rights, is to strengthen the Company's shareholder base with long-term strategic and qualified investors and at the same time in a quick and cost-effective way finance the Company's need for working capital, which has been slightly increased with the acquisition of Pilloxa. Also, the Board of Directors considers implementing a rights issue in current market conditions would entail a risk that the Company fail to meet its capital needs and by so fail to maintain an optimal capital structure. The Company's Board of Directors has made an overall assessment and carefully considered the possibility of raising capital through a rights issue. The Board of Directors has taken into account, among other things the high number of recent rights issues on the Nasdaq First North Premier Growth Market, and that the additional cost of a rights issue, such as advisory fees and underwriting compensation, would be unproportional to the limited size of the short term required capital. The conclusion of the Board of Directors' assessment is that the Directed Issue is objectively the best alternative for the Company and its shareholders.

The acquisition of Pilloxa

Pilloxa has developed a technology platform to support better medication adherence that pharmaceutical and healthcare companies use to design digital patient supports. The acquisition creates a new company in digital health that is well positioned to become a leading player in better and safer drug use. The purchase price amounts to approximately SEK 13.75 million and is paid through a directed offsetting issue of a total of 50,000,000 shares in iZafe ("Compensation Shares"). The subscription price for the Compensations Shares amounts to SEK 0.275. The basis for the subscription price is the share's market value based on the closing price for the Company's share of series B on the Nasdaq First North Premier Growth Market on Friday November 25, 2022.

Through the acquisition of Pilloxa, we are taking an important step towards our vision of improved health with better adherence. This creates an attractive and complete offer, access to a larger customer base and more sales channels. Through the Directed Issue, we are bringing in more strong owners to iZafe, and the warrants awarded to all shareholders are expected to provide a capital injection at the beginning of 2023. We will now increase the pace of sales of the joint company's products and services towards all our different customer categories. Together, we are creating a very strong offer within the framework of digital health, says Anders Segerström, CEO of iZafe.

With Pilloxa's digital offering and long-term collaboration with the pharmaceutical industry, we can together offer a comprehensive solution for patients, healthcare staff and the pharmaceutical industry. Pilloxa's promise to our customers, SME pharmaceutical companies, is a complete digital solution for patient support within one month of the first customer meeting. We are therefore used to rapid integrations and will immediately begin work on offering a joint digital solution, says Helena Rönnqvist, CEO at Pilloxa.

Incorrect or deficient medication is a major and costly problem for the individual, healthcare and for pharmaceutical companies, and costs society significant sums. Offering patients support to take their medication correctly has been shown to be an effective way to achieve better medical outcomes. Both iZafe and Pilloxa today offer solutions that support patients in safe medical treatment. The merger means a broader and more attractive offer to healthcare providers, patients, the pharmaceutical industry, and consumers, broadens the customer base and is expected to contribute to accelerated market penetration through clear sales and margin synergies.

Warrants to existing shareholders of iZafe

The Company has decided to distribute 76,890,165 warrants of series TO13B to all shareholders in the Company after the acquisition of Pilloxa in order to capitalize the Company and to compensate for the dilution from the Directed Issue. The warrants are subscribed by the Company and will be distributed free of charge to existing shareholders in the Company, where the Company's existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date. The Board of Directors has been authorized to determine the record date, thus information about the record date for the allotment of warrants of series TO13B will be communicated via a separate press release.

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023 to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

Terms, number of shares, share capital and dilution

Through the acquisition of Pilloxa, the number of shares in the Company increases by 50,000,000 B shares, from 82,946,996 shares (600,000 A shares and 82,346,996 B shares) to 132,946,996 shares, and the share capital will increase by SEK 10,000,000.00, from SEK 16,589,399.20 to SEK 26,589,399.20. The issue of shares as a result of the acquisition of Pilloxa entails a dilution for the Company's existing shareholders of approximately 37.61 percent.

The Directed Issue comprises 20,833,334 units, each unit consisting of one (1) share and two (2) warrants of series TO13B. The Directed Issue will increase the number of shares in the Company by 20,833,334 shares, from 132,946,996 shares to 153,780,330 shares, and the share capital will increase by SEK 4,166,667.80, from SEK 26,589,399.20 to SEK 30,756,066.00. The Directed Issue entails a dilution for the Company's existing shareholders of approximately 13.55 percent.

As a result of the acquisition and the Directed Issue, the total number of shares in the Company will increase by 70,833,334 shares, from 82,946,996 shares to 153,780,330 shares, and the share capital will increase by SEK 14,166,666.80, from SEK 16,589,399.20 to 30,756,066.00 SEK. Which entails a total dilution for the Company's existing shareholders of approximately 46.06 percent.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company after the completion of the acquisition and the Directed Issue. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the acquisition of Pilloxa and the Directed Issue.

About Us

iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers.

“iZafe and the medicine robot Dosell are the only products on the market that can handle the dose bags that we deliver to our customers in outpatient and inpatient care. We are happy to develop the collaboration with iZafe, which is completely in line with our business concept of offering technical solutions to customers in public and private healthcare”, says John Patrick Berlips, licensed physician and founder of ApoEx.

ApoEx supplies dose bags to 3,500 patients and hospitals in several of the country's regions. In Stockholm, the company produces the sachets that, among others, Aleris uses in its healthcare deliveries.

“ApoEx offers smart comprehensive solutions of goods and services for both private and public healthcare and is therefore the right partner for us. As iZafe is currently in an expansive phase, our strategic partnerships are absolutely crucial for us. With these collaborations, we can more effectively develop successful solutions together”, says Anders Segerström, CEO of iZafe.

About ApoEx
ApoEx was founded in 2010 with the aim of simplifying and improving care. We have developed most solutions in close dialogue with our customers and the business is characterized by customer-driven innovation and the attitude that nothing is impossible. Over the years, thousands of healthcare companies in the private and public sector have chosen ApoEx as their strategic partner for the supply of medicines and consumables.

About Us

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group’s quarterly report Q3, July-September 2022

iZafe Group AB (publ.) – presents today, November 7, its report for the third quarter of 2022.

Summary of financial performance

Net sales for the quarter amounted to SEK 75 (38) thousand. The quarter's net sales consist of revenues related to the sale of the digital pharmaceutical robot Dosell.
Operating profit for the quarter amounted to SEK -5,680 (-5,342) thousand.
Profit after financial items for the quarter amounted to SEK -5,751 (-6,183) thousand.
Cash flow for the period amounted to SEK -4,513 (-6,475) thousand.
Earnings per share for the quarter before / after dilution amounted to SEK -0.1 (-0.2).
Equity per share at the end of the period amounted to SEK 0.3 (1.5).
The equity ratio at the end of the period was 75.0 (62.3) percent.

Significant events during the quarter

The company has signed a cooperation agreement with the welfare platform Avanto Care. The collaboration means that iZafe's products are integrated with Avanto Care's platform and gives the opportunity to work more proactively with the users' medication.
With our partners Careium AS and Hepro AS, 20 and 25 Dosell have respectively been implemented in new municipalities in Norway.
Together with Aleris, the Company has started a pilot project for safer medication management. The goal is to introduce Dosell for the patient group that has advanced healthcare at home. During the quarter, 30 patients were introduced to the pharmaceutical robot.

Significant events after the end of the quarter

During quarter four 2022, 12,075,688 warrants of series TO10B were exercised, representing approximately 34.1 percent of outstanding warrants. The subscription price amounted to SEK 0.26 per B-share and raised approximately SEK 3.1 million for the company before issue costs
The company has signed a cooperation agreement with Medcam AB, which sells medical devices to the healthcare sector in the Nordic region and Europe. The primary focus will be on the Dutch market, but the potential for the company to enter several countries exists in the near future.

COMMENTS FROM THE CEO
A lot has happened in the last quarter and we continue to make strides on our growth journey – both in the Swedish and European markets.
There is a growing demand for products and services that enable more digital care where medication and adherence are crucial.

Our Dosell vending machine continues to do well across the board and we are pleased to see strong demand and positive sales for Dosell consumer through Apoteket AB. The packaging and sales of our consumer product have been crucial in moving forward in dialogues with potential partners in other European countries. We have now accumulated enough experience and documentation to streamline the processes and reduce the costs associated with selling and marketing Dosell to consumers.

Our entire business concept is based on sales through specific partners who handle sales, warehousing, logistics and marketing. With a focus on ensuring quality in small volumes at first, we will be able to scale up the volume and sales of many of our partners in more markets as early as next year.
We have also started the implementation of Dosell at Aleris ASIH (Advanced Home Healthcare) which is very exciting. The whole ASIH market relies on a different type of Dosell than the procured Dosell at regional level. It has a different design that makes it very difficult for the drug robots to handle. We can proudly say that we are the only pharmaceutical robot on the Swedish market that can handle these dose bags.

We have a clear vision to offer proactive holistic health for many more providers and patients, with a focus on these four elements:

Securing established and professional owners who can support the company with long-term external funding
Strategic acquisitions that broaden our offering and portfolio ensuring the right medicine at the right time
3.Managing personal data and ensuring that the necessary integration work is implemented
Internationalization towards new markets and together with both existing and new partners

Since October, we have a new Board in place that will help us to realize the action plan ahead. We have secured expertise and networks around finance, digitization, GDPR, sensitive data management and legal requirements. There we now have a clear strategy and plan for acquisitions, integrations with other wellbeing platforms, sales and internationalization.

The potential acquisition of Pilloxa is very interesting as we see that there is a strong demand around the ability to ensure adherence through all stages of the patient journey and to be able to integrate data into wellbeing platforms and home monitoring. The status on this is that we have completed due diligence and are now in the final stages of negotiations.

Another milestone during the quarter is our entry into the Dutch market. The Netherlands is an important market for us as they are the foremost pioneers in dose packaged medicine. The majority of all manufacturers of dose packaging machines are based in the Netherlands, which means that once we have been successful there, there will be positive knock-on effects throughout Europe.

Finally, I would like to mention that we are in dialogue with several other players in key markets in Europe, with whom we hope to have a clear agreement shortly. In this way, iZafe can in the future contribute broadly to a more proactive holistic approach to health, resulting in better health for more people. Socially sustainable value for society – that's really important.

About Us

IZafe Group Q3 ENG

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with Medcam AB, which sells medical technology products to healthcare in the Nordics and Europe. In the first place, the focus will be on the Dutch market, but the company has the potential for several countries in the near term.

"We have a high demand for products that enable a more digital healthcare where medication and compliance are an important factor. The pharmaceutical robot Dosell is a perfect complement to this, ensuring compliance in a safe way, while being integrated to enable more proactive and digital care.
The Dutch market has very great potential and we are starting this collaboration, as the demand from our customers is high for pharmaceutical robots", says Robert Camara, CEO of Medcam.

"The Dutch market has long been a goal for us to enter, as it is the country that has come the furthest in Europe regarding medication in sachets. We are now ready to start more collaborations that enable us to expand to several markets and look forward to starting work with Medcam and their customers", says Anders Segerström, CEO of iZafe Group.

About Medcam
MedCam AB markets and sells medical technology products and focuses on high quality products from stable suppliers. The company's business concept is to supply the Nordic and European market with high-quality products at good prices with high service.
The company's suppliers are located all over the world, i.a. USA, France, Germany and China. Medcam constantly strives to be able to satisfy customers' needs and demand and continuously searches the market, in order to be able to offer better and innovative products now and for the future.
For more information, read more at www.medcam.se

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe Group AB (publ.) (”iZafe” or the ”Company”) today announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021. In total, 12,072,688 warrants of series TO10B were exercised, corresponding to approximately 34.1 percent of the total number of outstanding warrants of series TO10B, for subscription of 12,072,688 B-shares at a subscription price of SEK 0.26 per B-share. iZafe will receive approximately SEK 3.14 million before issuing costs through the exercise of the warrants of series TO10B.

Background
The subscription period for exercise of the warrants of series TO10B took place from September 27, 2022, up to and including October 11, 2022. The subscription price per B-share for exercising the warrants of series TO10B was set to SEK 0.26.

In total, 12,072,688 warrants of series TO10B were exercised for subscription of 12,072,688 B-shares, meaning that approximately 34.1 percent of all outstanding warrants of series TO10B were exercised for subscription of B-shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.

Number of shares, share capital and dilution
Through the exercise of the warrants of series TO10B, the number of shares in iZafe increases by 12,072,688 B-shares, from 70,874,308 shares (consisting of 600,000 A-shares och 70,274,308
B-shares) to a total of 82,946,996 shares. The share capital will increase by SEK 2,414,537.60 from SEK 14,174,861.60 to SEK 16,589,399.20.

For existing shareholders who did not exercise any warrants of series TO10B, the dilution amounts to approximately 14.6 percent of the number of shares and approximately 13.7 percent of the number of votes in the Company.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.

About Us

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe and Aleris start pilot projects for safer medication

iZafe Group AB (publ.) announces today that it is starting a pilot project with Aleris. The aim of the project is to produce decision-making material for a potential introduction of the pharmaceutical robot Dosell in Aleris for the patient group advanced healthcare in the home (ASIH

In October will 30 patients in the advanced home healthcare, in Region Stockholm, will receive for the first time a robot that will help them take their medicine. The aim is to reduce the risk of medication mistreatment, underdosing and overdosing or mixing up medication. In some cases, the risk of abuse can also be reduced.

— Pharmaceutical robots mean major positive changes for patient safety. If the patient does not take their medication, an alarm is sent to our nurses, says Maria Frick, registered pharmacist at Aleri's local health care.

Aleris has investigated the possibility of introducing so-called pharmaceutical robots within advanced home healthcare in the Stockholm Region. A total of 30 Dosell pharmaceutical robots from iZafe have been purchased. During October, the pharmaceutical robot will be introduced to the first patient treated in advanced healthcare at home (ASIH).

— We see great opportunities with pharmaceutical robots in specialist healthcare. Innovation and technology that can help our patients to greater independence while increasing or maintaining patient safety is important to us, says Maria Frick.

It is the first time a pharmaceutical robot has been integrated into advanced home healthcare.

— We are extremely proud to continue to contribute to helping several patient groups and making everyday life easier with our unique pharmaceutical robot. We look forward to starting the implementation of Dosell at Aleris. After three months, an evaluation is carried out to see how many pharmaceutical robots the business wishes to bring in, says Anders Segerström, CEO iZafe Group.

For certain patient groups, the robot is an important aid. Last year, the poison information center received a number of calls about patients who, due to wrong dosage or mix-up, had taken the wrong medicine. 61 percent of them were recommended to seek medical care. Many serious overdoses are found in the group.

— A medication robot tells when a patient should take their medication, at the same time medication for future administration occasions is inaccessible, says Maria Frick.

Another advantage of pharmaceutical robots is increased efficiency and the opportunity to spend resources on more value-creating activities.

Not all patients in specialist healthcare are suitable for a medication robot, an assessment is always made and confirmed with the doctor that the patient can manage their medication with and that it is a suitable solution for this particular individual.

This is how a pharmaceutical robot works in specialist healthcare
The medication robot, no bigger than a shoebox, is placed in the patient's home. The robot is loaded with the patient's prescribed medication packaged in sachets. The medication robot reads the time for the next medication intake and at the correct date and time a dose bag is fed forward and thus becomes available to the patient. To remind you that it is time to take medicine, the robot signals with light and sound.

If for some reason the patient does not remove his dose bag from the robot, the patient's nurse will receive an alarm about this and then contact the patient, either through a phone call or a visit.

For further information contact:
Kenan Harbas, press manager Aleris, +46 707 834 203
Anders Segerström, CEO iZafe Group, +46 70-875 14 12

About Aleris
Aleri's vision is to lead the way to tomorrow's health and care. Through innovative solutions, we create opportunities for a better and healthier life while contributing to increased accessibility and social benefit. Aleris is a Scandinavian healthcare provider with two million patient visits a year and provides specialist healthcare at over 130 locations in Sweden, Norway and Denmark.

About Dosell
The pharmaceutical robot Dosell is a Swedish-made digital aid for safer medication at home and for residents in nursing homes. Dosell is integrated into welfare platforms and sold as one of several integrated digital aids via partners. Dosell notifies the patient when it is time to take the medication, and if the medication is not taken despite the reminders, Dosell alerts healthcare staff or relatives who can quickly prevent an injury from occurring as well as improve compliance and thereby minimize medication-related injuries.

About Us

iZafe and Aleris start pilot projects for safer medication

The Italian sachet market is starting to gain momentum

iZafe Group (publ.) hereby announces that the partner Remedio has sold its concept to 12 pharmacies which in a short time have 2,000 active customers who receive their medicines in sachets.

"Getting the medicine in sachets is completely new to the Italian market and our concept is based on local pharmacies purchasing a machine to enable their customers to have the medicine delivered in sachets. In a short time, we have now succeeded in installing machines for packing medicine into sachets in 12 pharmacies. These pharmacies have in turn gotten 2,000 of their customers to start getting their medicines delivered in sachets. Of these, about 95% are users in nursing homes. We currently have a rate of 2 new pharmacies a month installing a machine.

We will now start actively selling Dosell to these customers, but we will also start tests to introduce corportare version of Dosell, as most of our customers patients are now in nursing homes." says Alessandro Iadecola, CEO Remedio S.R.L.

"Getting several pharmacies to start packaging the medicines in sachets is absolutely crucial for Dosell, which is based on loading the medicine robot with these sachets. It will be exciting to follow the development on the Italian market, where it is now finally starting to gain momentum. Extra happy that so many nursing homes are starting to show interest in getting the medicine in sachets, as there are 3,000 nursing homes with over 300,000 beds in Italy." says Anders Segerström, CEO of iZafe Group AB.

About Us

The Italian sachet market is starting to gain momentum

The last day of trading with the warrants of series TO10B in iZafe Group AB is today, October 7, 2022

Today, October 7, 2022, is the last day of trading with the warrants of series TO10B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO10B runs up until October 11, 2022. Each warrant of series TO10B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO10B is SEK 0.26 per share of series B.

If all the warrants of series TO10B are exercised, the Company will receive approximately SEK 9.2 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than October 11, 2022. Alternatively, the holder may sell the warrants, no later than today, October 7, 2022. Please be aware that certain nominees may close their subscriptions earlier than October 11, 2022. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.

Summarized terms for the warrants of series TO10B:

Exercise period: September 27, 2022 – October 11, 2022.

Exercise price: SEK 0.26 per share of series B.

Issue size: 35,435,674 warrants of series TO10B, which entitles to subscription of 35,435,674 shares of series B. If all the warrants are exercised, The Company will receive approximately SEK 9.2 million before issuing costs.

Last day for trading warrants of series TO10B: October 7, 2022.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 7,087,134.80, from SEK 14,174,861.60 to SEK 21,261,996.40. If all warrants are exercised the number of shares will increase with 35,435,674 shares of series B, in total the number of shares in the Company will increase from 70,874,308 shares to 106,309,982 shares (600,000 shares of series A and 105,709,982 shares of series B). The dilution at full exercise of all warrants amounts to approximately 33.33 percent of the number of shares and 31.72 percent of the votes in the Company.
Note that the warrants of series TO10B that are not exercised at the latest October 11, 2022, or sold at the latest October 7, 2022, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

About Us

The last day of trading with the warrants of series TO10B in iZafe Group AB is today, October 7, 2022